Vivos Q3 revenue $6.8M (+78% seq, +76% YoY); operating loss widens to $4.7M

Vivos Therapeutics, Inc.

2025-Q3 EPS reported -$1.49 revenue$13,619,000

Revenue of $6.8M in Q3 2025, driven by first full quarter of Sleep Center of Nevada (SCN) acquisition; SCN added $2.2M diagnostic and $1.3M treatment revenue.
Gross profit $3.9M (58% margin, down from 60% YoY); operating expenses $8.7M (+74% YoY) on SCN-related headcount and depreciation.
Operating loss $4.7M ($2.6M in Q3 2024); cash $3.1M at Sept 30, 2025 vs $6.3M at Dec 31, 2024.
Entered management agreement with MISleep Solutions for a joint location in Auburn Hills, MI, seeing patients from December; owns supermajority equity.
Conference call at 5:00 pm ET; replay available until Dec 3, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.